Compare with PODDAR PIGM. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GENERIC PHARMASEC vs PODDAR PIGM. - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GENERIC PHARMASEC PODDAR PIGM. GENERIC PHARMASEC/
PODDAR PIGM.
 
P/E (TTM) x 87.5 11.3 771.9% View Chart
P/BV x 8.7 1.3 688.6% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 GENERIC PHARMASEC   PODDAR PIGM.
EQUITY SHARE DATA
    GENERIC PHARMASEC
Mar-21
PODDAR PIGM.
Mar-21
GENERIC PHARMASEC/
PODDAR PIGM.
5-Yr Chart
Click to enlarge
High Rs17226 7.4%   
Low Rs7112 6.5%   
Sales per share (Unadj.) Rs0.8213.8 0.4%  
Earnings per share (Unadj.) Rs022.3 0.2%  
Cash flow per share (Unadj.) Rs024.3 0.2%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Avg Dividend yield %01.5 0.0%  
Book value per share (Unadj.) Rs0.7229.0 0.3%  
Shares outstanding (eoy) m276.8610.61 2,609.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x15.60.8 1,967.4%   
Avg P/E ratio x263.57.6 3,476.0%  
P/CF ratio (eoy) x260.97.0 3,748.2%  
Price / Book Value ratio x16.00.7 2,172.6%  
Dividend payout %011.2 0.0%   
Avg Mkt Cap Rs m3,3141,794 184.8%   
No. of employees `000NANA-   
Total wages/salary Rs m2256 0.7%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m2132,269 9.4%  
Other income Rs m336 9.0%   
Total revenues Rs m2162,305 9.4%   
Gross profit Rs m12299 4.0%  
Depreciation Rs m021 0.6%   
Interest Rs m05 0.0%   
Profit before tax Rs m15309 4.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m373 3.5%   
Profit after tax Rs m13237 5.3%  
Gross profit margin %5.613.2 42.5%  
Effective tax rate %16.723.5 70.9%   
Net profit margin %5.910.4 56.6%  
BALANCE SHEET DATA
Current assets Rs m2681,740 15.4%   
Current liabilities Rs m72528 13.6%   
Net working cap to sales %92.153.4 172.4%  
Current ratio x3.73.3 113.5%  
Inventory Days Days148156 94.9%  
Debtors Days Days128,898,635656 19,648,324.8%  
Net fixed assets Rs m101,254 0.8%   
Share capital Rs m277106 260.9%   
"Free" reserves Rs m-702,323 -3.0%   
Net worth Rs m2072,430 8.5%   
Long term debt Rs m00-   
Total assets Rs m2782,993 9.3%  
Interest coverage xNM64.4-  
Debt to equity ratio x00-  
Sales to assets ratio x0.80.8 101.1%   
Return on assets %4.58.1 56.0%  
Return on equity %6.19.7 62.5%  
Return on capital %7.312.9 56.5%  
Exports to sales %00-   
Imports to sales %028.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA649 0.0%   
Fx inflow Rs m0662 0.0%   
Fx outflow Rs m0649 0.0%   
Net fx Rs m014 0.0%   
CASH FLOW
From Operations Rs m-21243 -8.8%  
From Investments Rs m-14-265 5.3%  
From Financial Activity Rs m45-3 -1,624.5%  
Net Cashflow Rs m10-25 -37.8%  

Share Holding

Indian Promoters % 0.0 62.4 -  
Foreign collaborators % 60.0 0.0 -  
Indian inst/Mut Fund % 0.0 1.2 -  
FIIs % 0.0 1.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 40.0 37.6 106.6%  
Shareholders   17,121 13,054 131.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GENERIC PHARMASEC With:   BAGADIA COLOURCHEM  AKSHARCHEM  SHREYAS INTE  DYNAMIC IND.  HINDPRAKASH INDUSTRIES  



Today's Market

L&T, ReNew Power Join Hands for Green Hydrogen Biz, Cadila's Covid Vaccine, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note yesterday. Benchmark indices witnessed heavy buying for the second consecutive session, even as world markets grappled with Omicron fears.

Related Views on News

Ami Organics Stock Makes Impressive Debut on Bourses. Lists at 49% Premium (Views On News)

Sep 14, 2021

Shares of Ami Organics makes a strong debut on the stock exchange. Did you bid for the IPO?

Chemplast Sanmar Makes Flat Debut as IPO Frenzy Fizzles Out (Views On News)

Aug 24, 2021

The grey market had indicated a flat listing for shares of Chemplast Sanmar ahead of its debut.

Understanding Aarti Industries' Demerger (Views On News)

Aug 20, 2021

Will the pharma unit's demerger unlock value for shareholders?

What Next for Devyani, Zomato, & Tatva Chintan Pharma After Stellar IPO Gains? (Views On News)

Aug 20, 2021

What's the outlook for Devyani, Zomato, and Tatva Chintan Pharma after robust listings?

Pidilite Results Review: Net Profit Spikes as Sales Rise 121% (Views On News)

Aug 12, 2021

Pidilite posts strong sales growth and a multi-fold jump in bottomline.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

5 Indian Companies Embracing Blockchain Technology(Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GENERIC PHARMASEC SHARE PRICE


Dec 2, 2021 (Close)

TRACK GENERIC PHARMASEC

  • Track your investment in GENERIC PHARMASEC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GENERIC PHARMASEC

GENERIC PHARMASEC 5-YR ANALYSIS

COMPARE GENERIC PHARMASEC WITH

MARKET STATS